Second-line drug therapy plus targeted radiation for advanced liver cancer
Part of Cancer, Digestive system clinical trials.
This trial is testing a new approach for people with advanced liver cancer: giving a second-line drug therapy along with targeted radiation (SBRT) to the spots that are growing. The goal is to control the cancer better and possibly help you live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are physically strong enough to be up and about most of the day (KPS 80 or higher).
- You have been diagnosed with hepatocellular carcinoma (the most common type of liver cancer).
- Your cancer started growing again during or after your first standard treatment (using bevacizumab plus atezolizumab/sintilimab, or lenvatinib with or without a PD-1 inhibitor).
- The growth is limited to 1 to 5 new or growing spots in up to 3 areas (like the liver, lungs, or lymph nodes), and each spot is 5 cm or smaller.
- Your liver function is good enough (Child-Pugh score of 7 or less), and your blood counts are in the required range.
- You have not had any active bleeding or severe side effects from your previous treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation (SBRT), an immunotherapy drug (PD-L1 inhibitor), and a targeted therapy (lenvatinib) for people with liver cancer that has spread to abdominal lymph nodes. It may be an option if you haven't taken certain immunotherapies before or if your cancer progressed after them.
This trial tests a combination of liver-directed treatments and immunotherapy with a targeted drug for people whose liver cancer has spread to a few other organs. It aims to shrink tumors and improve outcomes.
This trial tests adding two immunotherapy and anti-angiogenesis drugs (atezolizumab and bevacizumab) to standard photon radiation for people with liver cancer that cannot be surgically removed. It aims to see if this combination can shrink tumors and improve outcomes.
This trial tests a combination of radiation therapy with two drugs (QL1706 and bevacizumab) for people with liver cancer that hasn't spread to other parts of the body but can't be surgically removed. The goal is to see if this approach can shrink or control the tumor.
This trial tests whether giving radiation to a few growing cancer spots while continuing your current treatment works better than switching to a new treatment right away. It's for people whose advanced liver cancer has only barely started to progress on their first therapy.
This trial tests whether adding targeted radiation to liver cancer patients who have limited progression after initial immunotherapy can help control the disease. It is for people with hepatocellular carcinoma (HCC) whose cancer has started to grow in just a few spots after their first PD-1 treatment.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.